ClearPoint Neuro
CLPT
64 hedge funds and large institutions have $49.5M invested in ClearPoint Neuro in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 14 closing their positions.
78% more call options, than puts
Call options by funds: $703K | Put options by funds: $396K
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
0.1% less ownership
Funds ownership: 20.18% → 20.07% (-0.1%)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
4% less funds holding
Funds holding: 67 → 64 (-3)
7% less capital invested
Capital invested by funds: $53.4M → $49.5M (-$3.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.41M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$1.04M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$749K |
| 4 |
Renaissance Technologies
New York
|
+$653K |
| 5 |
Morgan Stanley
New York
|
+$459K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$1.5M |
| 2 |
GPC
Guardian Point Capital
Charlottesville,
Virginia
|
-$1.12M |
| 3 |
Two Sigma Advisers
New York
|
-$652K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$590K |
| 5 |
KMC
Kirr Marbach & Co
Columbus,
Indiana
|
-$496K |
CLPT Hedge Fund Activity: Q1 2022 in Review
64 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ClearPoint Neuro (CLPT) for Q1 2022, worth a combined $49.5M — down 7.3% from $53.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CLPT and 13 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 22 added.
The largest buyer was Vanguard Group, adding an estimated $1.41M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $1.5M sold.
- 64 institutional investors held ClearPoint Neuro (CLPT) as of Q1 2022, down from 67 in Q4 2021.
- Funds reported $49.5M of ClearPoint Neuro stock for Q1 2022, down 7.3% quarter-over-quarter.
- 13 funds opened new ClearPoint Neuro positions in Q1 2022 and 14 closed out, a net change of -1 holder.
- The largest ClearPoint Neuro buyer in Q1 2022 was Vanguard Group, an estimated $1.41M added.
- The largest ClearPoint Neuro seller in Q1 2022 was Two Sigma Investments, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2022.